Original Articles

Grading of lymphocyte infiltrating tumor can be used as a prognosis factor compared to T Pathology and N Pathology on recurrency of colon cancer

Putu Ayu Saraswati , Vicky Sumarki Budipramana, Alphania Rahniayu

Putu Ayu Saraswati
Trainee of Digestive Surgery, Surgery Department of Universitas Airlangga, Surabaya, Indonesia. Email: ayusaraswati84@gmail.com

Vicky Sumarki Budipramana
General Surgery Department Airlangga Medical Faculty, Soetomo General Hospital Surabaya, Indonesia

Alphania Rahniayu
Pathology Anatomy Department Airlangga Medical Faculty, Soetomo General Hospital, Surabaya, Indonesia
Online First: February 25, 2021 | Cite this Article
Saraswati, P., Budipramana, V., Rahniayu, A. 2021. Grading of lymphocyte infiltrating tumor can be used as a prognosis factor compared to T Pathology and N Pathology on recurrency of colon cancer. Indonesia Journal of Biomedical Science 15(1): 39-42. DOI:10.15562/ijbs.v15i1.280


Background: 30-50% of colon cancer patients will experience recurrence and then die. Several factors that can be used as a prognosis for recurrence are tumor staging, number of lymph nodes resected, high pT, and grading of TILs as an immune response that is useful for suppressing tumor growth. This study aimed to determine whether the TILs grading can be used as a prognostic factor for recurrence than pT and pN.

Methods: This study used a descriptive retrospective study with all colon cancer patients who had hemicolectomy R0 right and left and patients who had received chemotherapy folfox who experienced recurrence at Dr. Soetomo Surabaya. Data were analyzed using SPSS version 25.0 for Windows.

Results: It was found that 33 people (32.4%) experienced a recurrence of less than 2 years and 69 people (67.9%) experienced a recurrence of 2-5 years. Low-grade TILs were 37 people (32.4%), and high TILs were 65 (63.7%). Patients with low-grade TILs at most 21 people (56.7%) will experience a recurrence of less than 2 years, while patients with high-grade TILs at most 53 people (81.5%) will experience a recurrence in years 2 - 5. pT4 has a recurrence of less than 2 years as many as 6 people (46.2%), less than pT4 with a recurrence of 2-5 years, namely 7 people (58.3%) while pT3 who experienced a recurrence of less than 2 years, the number was higher than pT4, namely 22 people (32.8%). pN0 will experience the highest recurrence in years 2-5 as many as 37 people (80.4%), while pN2 will experience the highest recurrence in less than 2 years as many as 14 people (66.6%). Grading TILs were significant (p = 0.018) in determining the prognosis than pT (p = 0.204) and pN (p = 0.083) in the first 2 years.

Conclusion: Grading of TILs can be a prognostic factor for colon cancer recurrence in only the first 2 years.

References

Guraya SY. Pattern, Stage, and Time of Recurrent Colorectal Cancer After Curative Surgery. Clin Colorectal Cancer. 2019;18(2):e223-e228.

Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G, et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer. 2014;110(6):1595-605.

Böckelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol. 2015;54(1):5-16.

Chan LF, Sadahiro S, Suzuki T, Okada K, Miyakita H, Yamamoto S, et al. Tissue-Infiltrating Lymphocytes as a Predictive Factor for Recurrence in Patients with Curatively Resected Colon Cancer: A Propensity Score Matching Analysis. Oncology. 2020;98(10):680-688.

Prabawa IPY, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, et al. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. Asian Pac J Cancer Prev. 2019;20(3):863-868.

Wiranata S, Anjani IAW, Saputra IPGS, Sadvika IGAS, Prabawa IPY, Supadmanaba IG, et al. Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as a Stage Determination in Breast Cancer. Open Access Maced J Med Sci. 2020;8(B):1058-1063.

Maeda H, Kashiwabara K, Aoyama T, Oba K, Honda M, Mayanagi S, et al. Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials. J Cancer. 2017;8(19):4057-4064.

Tsikitis VL, Larson DW, Huebner M, Lohse CM, Thompson PA. Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer. 2014;14:336.

Ong W, Zhao R, Lui B, Tan W, Ebrahimi A, Clark JR, et al. Prognostic significance of lymph node density in squamous cell carcinoma of the tongue. Head Neck. 2016;38 Suppl 1:E859-66.

Zhang ZY, Gao W, Luo QF, Yin XW, Basnet S, Dai ZL, et al. A nomogram improves AJCC stages for colorectal cancers by introducing CEA, modified lymph node ratio and negative lymph node count. Sci Rep. 2016;6:39028.

Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell. 2012;148(6):1081-1084.

Vermijlen D, Froelich CJ, Luo D, Suarez-Huerta N, Robaye B, Wisse E. Perforin and granzyme B induce apoptosis in FasL-resistant colon carcinoma cells. Cancer Immunol Immunother. 2001;50(4):212-217.

Fuchs TL, Sioson L, Sheen A, Jafari-Nejad K, Renaud CJ, Andrici J, et al. Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma: A Study of 1034 Patients. Am J Surg Pathol. 2020;44(4):536-544.

Jakubowska K, Koda M, Kisielewski W, Kańczuga-Koda L, Famulski W. Tumor-infiltrating lymphocytes in primary tumors of colorectal cancer and their metastases. Exp Ther Med. 2019;18(6):4904-4912.

Biragyn A, Lee-Chang C, Bodogai M. Generation and identification of tumor-evoked regulatory B cells. Methods Mol Biol. 2014;1190:271-289.

Morrison BJ, Steel JC, Morris JC. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells. BMC Cancer. 2018;18(1):469.

Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30(2):180-192.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.

Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558-62.

Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother. 2012;35(1):89-97.

Maeda H, Kashiwabara K, Aoyama T, Oba K, Honda M, Mayanagi S, et al. Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials. J Cancer. 2017;8(19):4057-4064.

He WZ, Hu WM, Kong PF, Yang L, Yang YZ, Xie QK, et al. Systemic neutrophil lymphocyte ratio and mismatch repair status in colorectal cancer patients: correlation and prognostic value. J Cancer. 2018;9(17):3093-3100.


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0